Publicaciones en colaboración con investigadores/as de Hospital San Pedro de Alcántara (15)

2023

  1. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

    American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247

2022

  1. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

    Clinical Gastroenterology and Hepatology, Vol. 20, Núm. 10, pp. 2243-2257

  2. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  3. Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg)

    Journal of Clinical Gastroenterology, Vol. 56, Núm. 2, pp. E98-E108

  4. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg)

    The American journal of gastroenterology, Vol. 116, Núm. 6, pp. 1220-1229

  2. European registry on helicobacter pylori management: Effectiveness of first and second-line treatment in Spain

    Antibiotics, Vol. 10, Núm. 1, pp. 1-15

2020

  1. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg)

    Helicobacter, Vol. 25, Núm. 5

  2. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 89-98

  3. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg)

    Helicobacter, Vol. 25, Núm. 3

2019

  1. Prevalence and Factors Associated with Fatigue in Patients with Inflammatory Bowel Disease: A Multicentre Study

    Journal of Crohn's and Colitis, Vol. 13, Núm. 8, pp. 996-1002

2017

  1. Erratum to “IV Spanish Consensus Conference on Helicobacter pylori infection treatment” <(Gastroenterol Hepatol (2016) 39 (697–721)> (Gastroenterologia y Hepatologia (S0210570516300589) (10.1016/j.gastrohep.2016.05.003))

    Gastroenterologia y Hepatologia

2016

  1. IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori

    Gastroenterologia y Hepatologia

2015

  1. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: The OPTRICON study

    Alimentary Pharmacology and Therapeutics, Vol. 41, Núm. 6, pp. 581-589

2013

  1. III Conferencia Española de Consenso sobre la infección por Helicobacter pylori

    Gastroenterologia y Hepatologia, Vol. 36, Núm. 5, pp. 340-374